Gregory R Fulcher,* John V Amerena,† Greg W Conner‡
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1 Department of Diabetes, Endocrinology and Metabolic Medicine, Level 3, Main Block, Royal North Shore Hospital, St Leonards, NSW 2065
- 2 Department of Clinical and BioMedical Sciences, University of Melbourne, Melbourne, VIC
- 3 Cardiovascular Diagnostic Services, Sydney, NSW.
Correspondence: gfulcher@med.usyd.edu.au
- 1. Fulcher GR, Conner GW, Amerena JV, et al. Prevention of cardiovascular disease: an evidence-based clinical aid [Focus document]. Med J Aust 2003; 179 (21 July): 1-16. <eMJA full text> <MJA full text>
- 2. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136: 161-172.
- 3. Hung J, for the Medical Issues Committee of the National Heart Foundation of Australia. Aspirin for cardiovascular disease prevention [position statement]. Med J Aust 2003; 179: 147-152. <eMJA full text> <MJA full text>
- 4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
- 5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
- 6. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol And Recurrent Events trial investigators. N Engl J Med 1996; 335: 1001-1009.
- 7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
- 8. National Prescribing Service. News 20 February 2002. Prescribing pointers: lipid-modifying therapy. Available at: www.nps.org.au/site.php?content=/html/news.php&news=/resources/NPS_News/news20#pp (accessed Jan 2004).
Online responses are no longer available. Please refer to our instructions for authors page for more information.